REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
11:10 AM | Friday | Sep 4, 2026 Business Wire

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

News Thumbnail
9:37 AM | Friday | Sep 4, 2026 Newsfile Corp

REGN 10-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

News Thumbnail
9:28 AM | Friday | Sep 4, 2026 Newsfile Corp

REGN DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail
11:00 AM | Thursday | Sep 3, 2026 GuruFocus

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

News Thumbnail
10:33 AM | Thursday | Sep 3, 2026 GlobeNewsWire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

News Thumbnail
10:07 AM | Thursday | Sep 3, 2026 PRNewsWire

REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt

News Thumbnail
10:00 AM | Thursday | Sep 3, 2026 PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

News Thumbnail
12:00 PM | Wednesday | Sep 2, 2026 GlobeNewsWire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

News Thumbnail
10:11 AM | Wednesday | Sep 2, 2026 PRNewsWire

REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026

News Thumbnail
9:02 AM | Wednesday | Sep 2, 2026 GlobeNewsWire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

News Thumbnail

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Business Wire

11:10 AM | Friday | Sep 4, 2026

news photo
Loading...

SAN DIEGO--(BUSINESS WIRE)---- $REGN #REGN--The case alleges Regeneron and its top executives made false and/or misleading statements to investors.

Read full article redirect
11:10 AM | Friday | Sep 4, 2026

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $REGN #REGN--The case alleges Regeneron and its top executives made false and/or misleading statements to investors.

Read full article arrow
News Thumbnail
9:37 AM | Friday | Sep 4, 2026

REGN 10-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

Newsfile Corp

San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

Read full article arrow
News Thumbnail
9:28 AM | Friday | Sep 4, 2026

REGN DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Newsfile Corp

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been... Read more

Read full article arrow
News Thumbnail
11:00 AM | Thursday | Sep 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

GuruFocus

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire

Read full article arrow
News Thumbnail
10:33 AM | Thursday | Sep 3, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire

LOS ANGELES, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read full article arrow
News Thumbnail
10:07 AM | Thursday | Sep 3, 2026

REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt

PRNewsWire

Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Sep 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

PRNewsWire

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).

Read full article arrow
News Thumbnail
12:00 PM | Wednesday | Sep 2, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewsWire

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.

Read full article arrow
News Thumbnail
10:11 AM | Wednesday | Sep 2, 2026

REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026

PRNewsWire

Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of failing its primary endpoint.

Read full article arrow
News Thumbnail
9:02 AM | Wednesday | Sep 2, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

GlobeNewsWire

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive.

Read full article arrow
News Thumbnail